Patents Assigned to Medigen Biotechnology Corporation
-
Patent number: 10842804Abstract: Muparfostat for use in reducing intrahepatic tumor recurrence and increasing disease-free survival period in a hepatocellular carcinoma patient with microvascular invasion after curative liver resection, while excluding HCC patients with no vascular invasion and HCC patients with macrovascular invasion, is disclosed. The hepatocellular carcinoma patient with microvascular invasion is identified by examining a resected liver tumor sample from the HCC patient for the presence of microvascular invasion in the sample.Type: GrantFiled: February 8, 2018Date of Patent: November 24, 2020Assignee: Medigen Biotechnology CorporationInventors: Stanley Chang, Kuan-Lang Lai
-
Patent number: 9890206Abstract: An antibody, or a binding fragment of the antibody, against H1N1 virus, includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains complementarity determining regions (CDR) that have the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; and wherein the light chain variable region contains complementarity determining regions that have the amino acid sequences of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. A method for treating or preventing H1N1 infection in a subject includes administering to the subject the antibody or the binding fragment of the antibody.Type: GrantFiled: August 20, 2015Date of Patent: February 13, 2018Assignee: Medigen Biotechnology CorporationInventors: Young-Sun Lin, Kuei-Tai Lai, Huei-Luen Huang, Hsiang-Ting Hsu, Wan-Chen Chen, Ya-Lin Chen, Chia-Wen Wong
-
Publication number: 20170051046Abstract: An antibody, or a binding fragment of the antibody, against H1N1 virus, includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains complementarity determining regions (CDR) that have the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; and wherein the light chain variable region contains complementarity determining regions that have the amino acid sequences of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. A method for treating or preventing H1N1 infection in a subject includes administering to the subject the antibody or the binding fragment of the antibody.Type: ApplicationFiled: August 20, 2015Publication date: February 23, 2017Applicant: MEDIGEN BIOTECHNOLOGY CORPORATIONInventors: Young-Sun Lin, Kuei-Tai Lai, Huei-Luen Huang, Hsiang-Ting Hsu, Wan-Chen Chen, Ya-Lin Chen, Chia-Wen Wong
-
Patent number: 7507532Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.Type: GrantFiled: March 7, 2005Date of Patent: March 24, 2009Assignee: Medigen Biotechnology CorporationInventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li, Chih-Ping Hsu, Pei-Hsun Ho
-
Publication number: 20080020386Abstract: A method for determining the human leukocyte antigen (HLA) genotype of a nucleic acid sample, comprises: contacting a nucleic acid sample with at least one nucleic acid primer set and subjecting the mixture to a nucleic acid amplification reaction; determining the size of any amplification products produced in the amplification reaction; and correlating the presence and/or absence of specific amplification products with the presence and/or absence of specific sequence polymorphisms in the nucleic acid sample. At least one of the primer sets is a multi-specific primer set comprising at least one sequence-specific forward primer and at least one sequence-specific reverse primer and being adapted to amplify two or more specific target sequences in the nucleic acid sample. Each of the specific target sequences comprises a sequence polymorphism that is known to be associated with an HLA allele and which may be present in the nucleic acid sample to be genotyped.Type: ApplicationFiled: March 28, 2007Publication date: January 24, 2008Applicant: MEDIGEN BIOTECHNOLOGY CORPORATIONInventors: Chaw Yuan Michael Chen, Yen-Chin Chen, Wei-Ying Kuo, Chiao-Chien Hung
-
Publication number: 20060068411Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.Type: ApplicationFiled: March 7, 2005Publication date: March 30, 2006Applicant: Medigen Biotechnology CorporationInventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li, Chih-Ping Hsu, Pei-Hsun Ho